PDT Partners’s Cymabay Therapeutics CBAY Stock Holding History

PDT Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-58,035	Closed	-$180K	–	1200
2022 Q1	$180K	Hold	58,035	–	–	0.02%	829
2021 Q4	$196K	Buy	+58,035	New	+$220K	0.01%	767
2020 Q4	–	Sell	-26,799	Closed	-$194K	–	885
2020 Q3	$194K	Buy	+26,799	New	+$143K	0.01%	632
2020 Q1	–	Sell	-14,200	Closed	-$28K	–	894
2019 Q4	$28K	Buy	+14,200	New	+$53.3K	﹤0.01%	703
2015 Q3	–	Sell	-27,900	Closed	-$75K	–	1632
2015 Q2	$75K	Buy	27,900 +15,400	+123%	+$63.2K	﹤0.01%	1307
2015 Q1	$87K	Buy	+12,500	New	+$120K	﹤0.01%	1332

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

PDT Partners's CBAY Position: Q2 2022 in Review

PDT Partners sold out of Cymabay Therapeutics (CBAY) in Q2 2022, closing a stake of 58,035 shares — an estimated $180K sold.

PDT Partners first reported a position in CBAY in Q1 2015 and held it in 6 quarters. The position peaked at $196K in Q4 2021. 106 funds tracked by Wall St. Rank hold CBAY as of Q2 2022.

PDT Partners reported no remaining Cymabay Therapeutics position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 58,035 Cymabay Therapeutics shares in Q2 2022, an estimated $180K.
PDT Partners first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 6 quarters.
PDT Partners's Cymabay Therapeutics position peaked at $196K in Q4 2021.
106 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.